H.C. Wainwright raised the firm’s price target on Stoke Therapeutics (STOK) to $47 from $35 and keeps a Buy rating on the shares. Stoke and Biogen (BIIB) announced a collaboration deal on the development of zorevunersen, with Stoke receiving $165M upfront along with other development and milestone payments, with tiered royalties from low double-digit to high teens on potential net sales, the analyst tells investors in a research note. The firm views the deal as a A “win-win for both the parties, and especially for Stoke.” The news not only validates the science and the mechanism of action of zorevunersen, “but takes a huge pressure off the commercial development front,” contends H.C. Wainwright.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Biogen, Stoke Therapeutics announce zorevunersen commercialization agreement
- Stoke Therapeutics negative reaction after STK-001 update overdone, says Chardan
- Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study
- Stoke Therapeutics finalizes EMPEROR study program with regulatory agencies
- GeneDx (WGS), An Emerging Powerhouse in Genomics Sees Explosive Growth